Iron rims around MS lesions show up in parts of the brain but not in the spinal cord, so their use as a universal marker for disease activity and prognosis is limited.
Researchers looked at brain and spinal cord tissue from 46 people who had MS after they died. They did not find iron rims in any of the 152 spinal cord lesions studied, even though many of those lesions were still active (meaning inflammation was ongoing). In the brain, iron rims were common in subcortical white matter lesions (around 80% had rims) and were present in about 21% of cortical (surface) brain lesions. The iron rims in the brain tended to appear in deeper layers of cortex where myelin (the nerve insulation) is thicker, which suggests these rims relate to where myelin and certain immune cells are located. Overall, the study shows iron rims are not a general feature of all MS damage but depend on the brain region and local tissue makeup.
People with MS and their caregivers should care because doctors sometimes use iron rims seen on MRI as a sign of long-term inflammation and worse prognosis; this study shows that absence of rims in the spinal cord doesn’t mean the disease is inactive there. Think of iron rims like a marker or badge that appears only in some neighborhoods of the brain but not in the spinal cord — not finding the badge in one place doesn’t mean there’s no problem. Neurologists and radiologists should consider where a lesion is located when interpreting iron rims, so they don’t over- or under-estimate disease activity. Patients getting MRI-based monitoring should ask whether scans cover brain areas where rims are likely to appear and understand that spinal cord lesions may be active even without rims. Caregivers can use this info to better discuss imaging results with clinicians and to advocate for comprehensive imaging and symptom-based care.
This study used tissue from people after death, which gives detailed answers but may not match exactly what live MRI scans show in every case. The number of certain lesion types (for example, cortical lesions with rims) was relatively small, so percentages may change with larger studies. Because the study is about where iron rims appear, it doesn't change treatments directly but means clinicians should use multiple signs (symptoms, different MRI features, and exams) to judge disease activity.
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read More5/1/2026
Study found fewer hospital diagnoses of antibody-positive autoimmune encephalitis during COVID-19, b
Read More3/1/2026
Study shows C5 inhibitors given during or soon after NMOSD attacks helped most patients stabilize or
Read More3/1/2026
Early OCT eye scans can often distinguish MOGAD from NMOSD optic neuritis, helping guide faster trea
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.